Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, People's Republic of China.
Onco Targets Ther. 2013 Nov 14;6:1659-66. doi: 10.2147/OTT.S53248. eCollection 2013.
Solitary plasmacytoma (SP) is a rare tumor with low incidence. The aim of this study was to investigate the clinical features, treatment strategies, and relative prognostic factors of 66 patients with SP. These patients made up 10.25% of the 644 patients with plasma cell dyscrasias treated at the Tianjin Medical University Cancer Institute and Hospital over the past 12 years. SP always presented with either solitary bone plasmacytoma (SBP) or extramedullary plasmacytoma (EMP), as determined by the location of the lesions. SBP occurred most frequently in the vertebral column and EMP in the upper respiratory tract. In addition to other factors, tumor size, serum M protein level, urinary Bence Jones protein level, and disease progression toward multiple myeloma were significantly different between the two groups (P<0.05). Larger tumor size (≥5 cm) was associated with poor prognosis of local control, multiple myeloma-free survival, overall survival and progression-free survival for SBP patients. Radiotherapy and serum β2 microglobulin <3.5 mg/L were favorable prognostic factors for local control, multiple myeloma-free survival, and progression-free survival in patients with EMP.
孤立性浆细胞瘤(SP)是一种罕见的肿瘤,发病率较低。本研究旨在探讨 66 例 SP 患者的临床特征、治疗策略及相关预后因素。这些患者占过去 12 年在天津医科大学肿瘤医院治疗的 644 例浆细胞异常患者的 10.25%。SP 通常表现为单一骨浆细胞瘤(SBP)或髓外浆细胞瘤(EMP),根据病变部位确定。SBP 最常发生于脊柱,EMP 最常发生于上呼吸道。除其他因素外,两组患者的肿瘤大小、血清 M 蛋白水平、尿本-周氏蛋白水平和向多发性骨髓瘤进展情况存在显著差异(P<0.05)。对于 SBP 患者,较大的肿瘤大小(≥5cm)与局部控制、无多发性骨髓瘤生存、总生存和无进展生存不良相关。对于 EMP 患者,放疗和血清β2 微球蛋白<3.5mg/L 是局部控制、无多发性骨髓瘤生存和无进展生存的有利预后因素。